UTRF licenses cell line commercial rights to CytoSen Therapeutics

UTRF NewThe University of Tennessee’s Research Foundation recently executed a license granting CytoSen Therapeutics Inc.  the commercial rights to use the K-562 cell lines to produce an innovative natural killer cell therapy that harnesses the power of a person’s own immune cells to help fight cancer. Read more here.

Tom Ballard

By Tom Ballard, Chief Alliance Officer,
Pershing Yoakley & Associates. P.C.

eNews & Updates

Sign up to receive posts via email.

Connect With Us

Upcoming Events

Links to Partners